A pioneer in regenerative medicine, International Stem Cell
Corporation (OTCQB: ISCO) strives to make a difference with its stem cell
technology called parthenogenesis. The biotechnology company uses unfertilized
eggs to create pluripotent human parthenogenetic stem cells (hPSC). These stem
cells have the power to turn into any cell, healing and replacing aged or
damaged cells. The possible indications for this technology range from cellular
treatment point to a breakthrough for the treatments of degenerative diseases
of the eye, nervous system, and liver. ISCO’s research and development team
strongly believe in the effectiveness of their stem cell solution in such
diseases as Parkinson’s, Corneal Blindness, and Ischemic Stroke. However,
completing the proper testing and sanctions necessary to commercialize the
company’s technology will take many years. In the meantime, ISCO derives
substantial revenue from its two subsidiaries: Lifeline Skin Care Inc. and
Lifeline Cell Technology, LLC.
Lifeline Skin Care Inc.(www.lifelineskincare.com) focuses on
developing and marketing anti-aging products using ISCO’s breakthrough stem
cell technology. The cosmetic company uses stem cells from unfertilized eggs to
create solutions that reverse aging, add elasticity, and improve damaged skin
cells. First, proteins are captured from these eggs and encased in micro
nanospheres for protection. Antioxidants, vitamins, and minerals are then added
for extra rejuvenation. Lifeline Skin Care’s products boost collagen production
for even, firm skin. Retailers like Amazon (NASDAQ: AMZN), cosmetic surgery
offices, spas, and international corporations sell these products, which adds
more revenue streams and exposure for ISCO.
ISCO’s other subsidiary, Lifeline Cell Technology, LLC.
(www.lifelinecelltech.com), develops and commercializes human cell culture
products. Academic, pharmaceutical, and government laboratories purchase these
products, such as frozen human cells and the material need for cultivation, for
disease testing and study. Lifeline Cell Technology offers epithelial,
hematopoietic, bladder, breast, kidney cells and more with the highest
guaranteed quality. According to the company, these cells will “out-perform any
other cells” out there.
Though ISCO eagerly waits for its proprietary
parthenogenesis technology to gain global allowance, the company effectively
uses its two subsidiaries for a steady revenue stream. The operating income for
both companies increased 65% to $1.67 million in 2015, with 2014 having $1.01
million. Lifeline Skin Care retained steady numbers while Lifeline Cell
Technology sales were up 15%. Overall, ISCO saw an 8% increase last year, as
compared to 2014. The company intends to continue using its scientific
breakthroughs and products toward contributing to regenerative medicine.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
